Progenity is a provider of highly-complex molecular diagnostic testing allowing healthcare providers to access the most advanced genomic technology to guide patient care at critical life stages.
Progenity stock has been up nearly 58% in the past five trading days and more than 170% since early October. As PROG keeps marching higher, is it too late for investors to jump in now?
